Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Spigelman

Showing results (381-390 of 424) with videos related to

Pageof 43
Sort By:
BMC Medicine|March 30, 2018
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
Acta Oncologica (Stockholm, Sweden)|April 16, 2013
Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007Camille Maringe, Sarah Walters, Bernard Rachet, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout miceR M Mihalek, P K Banerjee, E R Korpi, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
International Journal of Cancer|September 19, 2012
Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriersBente A Talseth-Palmer, Juul T Wijnen, Ingvild S Brenne, et al.
Familial Cancer|August 13, 2013
Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndromeMarry H Nieuwenhuis, C Marleen Kets, Maureen Murphy-Ryan, et al.
Nature Genetics|December 21, 2022
A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of beta cell function influencing type 2 diabetes riskAntje K Rottner, Yingying Ye, Elena Navarro-Guerrero, et al.
Journal of Medical Genetics|February 25, 1998
Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3S Olschwang, D Markie, S Seal, et al.
Pageof 43

Showing results (381-390 of 424) with videos related to

Sort By:
Pageof 43
BMC Medicine|March 30, 2018
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, et al.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
Acta Oncologica (Stockholm, Sweden)|April 16, 2013
Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007Camille Maringe, Sarah Walters, Bernard Rachet, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 27, 1999
Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout miceR M Mihalek, P K Banerjee, E R Korpi, et al.
The Lancet. Respiratory Medicine|November 17, 2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trialConor D Tweed, Rodney Dawson, Divan A Burger, et al.
International Journal of Cancer|September 19, 2012
Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriersBente A Talseth-Palmer, Juul T Wijnen, Ingvild S Brenne, et al.
Familial Cancer|August 13, 2013
Cancer risk and genotype-phenotype correlations in PTEN hamartoma tumor syndromeMarry H Nieuwenhuis, C Marleen Kets, Maureen Murphy-Ryan, et al.
Nature Genetics|December 21, 2022
A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of beta cell function influencing type 2 diabetes riskAntje K Rottner, Yingying Ye, Elena Navarro-Guerrero, et al.
Journal of Medical Genetics|February 25, 1998
Peutz-Jeghers disease: most, but not all, families are compatible with linkage to 19p13.3S Olschwang, D Markie, S Seal, et al.
Pageof 43